Among NSCLC cases with activating mutations in EGFR—a tyrosine kinase which activates cell growth and proliferation—multiple studies have shown the incidence of CNS metastasis is enriched, with rates some 3–32% higher than EGFR wild-type cases (EGFRwt) [2,3,4,5,6]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.